Navigation Links
Life Technologies Announces Redemption of 1.5% Convertible Senior Notes Due 2024

CARLSBAD, Calif., Jan. 13, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today that it has given notice of its intention to redeem all of the outstanding 1.5% Convertible Senior Notes due 2024 (the "2024 Convertible Notes") on February 15, 2012. As of December 31, 2011 there was $450,000,000 in aggregate principal amount of the 2024 Convertible Notes outstanding. The redemption notice provided includes CUSIP Numbers: 46185RAG5, 46185RAH3 and 46185RAK6.

(Logo: )

The 2024 Convertible Notes are convertible at any time prior to 5:00 p.m. Eastern Time, February 14, 2012 at a rate of 19.603 shares of common stock per $1,000 principal amount of the 2024 Convertible Notes surrendered. The 2024 Convertible Notes surrendered for conversion will be settled in cash and stock in accordance with the provisions of the indentures.

The U.S. Bank National Association, the trustee for the 2024 Convertible Notes, is mailing a Notice of Redemption to all registered holders of the 2024 Convertible Notes on January 13, 2012. Copies of such Notice of Redemption and additional information relating to the procedure for redemption and/or conversion of the 2024 Convertible Notes may be obtained from the U.S. Bank National Association by calling (800) 934-6802.

About Life Technologies (

Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses. For more information on how we are making a difference, please visit our website:


Contact Information:
Investor Relations



SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. RainDance Technologies Appoints Olex Vice President, System Development
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
5. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. Anthill Technologies Announces Agreement With Zafgen
9. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
10. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
11. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):